Home/Filings/4/0001415889-23-011523
4//SEC Filing

Yuan Qing Sarah 4

Accession 0001415889-23-011523

CIK 0001821323other

Filed

Jul 26, 8:00 PM ET

Accepted

Jul 27, 4:21 PM ET

Size

7.4 KB

Accession

0001415889-23-011523

Insider Transaction Report

Form 4
Period: 2023-07-27
Transactions
  • Exercise/Conversion

    Common Stock

    2023-07-27$19.24/sh+2,884$55,4882,884 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2023-07-272,8846,346 total
    Exercise: $19.24Exp: 2032-03-06Common Stock (2,884 underlying)
Footnotes (2)
  • [F1]The option vested as to 25% of the underlying shares of common stock on March 7, 2023, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
  • [F2]Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the "Reverse Split") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split.

Issuer

Sigilon Therapeutics, Inc.

CIK 0001821323

Entity typeother

Related Parties

1
  • filerCIK 0001907487

Filing Metadata

Form type
4
Filed
Jul 26, 8:00 PM ET
Accepted
Jul 27, 4:21 PM ET
Size
7.4 KB